Why had LION to revise the sales outlook again?
back to LION bioscience home
SitemapPrintable version of this documentContact LIONZur deutschen Version dieses Dokuments LION bioscience AG
Investors
Share Information
Financial Figures
Financial Reports
Corporate Governance
Business Model
Press & Ad hoc Releases
Speeches & Presentations
Financial Calendar
FAQs
Why had LION to revise its policy on timing of revenue recognition? What influence does the restatement have on LION´s Key Figures?
Why had LION to revise the sales outlook again?
When do the Bayer deals expire?
Which steps have been taken to reach profitability?
Why is LION listed on the German stock market as well as on Nasdaq?
What is LION’s business strategy?
When will LION reach profitability? What will the cash position be at that point?
What is an ADR?
Glossary
Info Service
Investor Contact
 

© 2004 LION bioscience AG
Disclaimer
Imprint/Contact
Contact Webmaster
Why had LION to revise the sales outlook again?
 

LION expects revenues of 19 to 20 million € for the current fiscal year 2003/2004. This revenue target is positively influenced by the announced revision of LION´s revenue recognition practice. The on-going slump in the life science informatics market, the weak U.S. dollar as well as a slower than anticipated market introduction of new products, continue to have an adverse effect on LION’s business. LION does not expect a significant change in this regard within the next six months.